文献速递肿瘤 PET/CT

局限性治疗后前列腺癌生化复发患者18F-DCFPyL PET/CT阳性预测因素

Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
PubMed 文献 · J Nucl Med · 2021-12-16

这项两机构研究纳入245例原发性局部治疗后生化复发且常规影像阴性的前列腺癌患者,行18F-DCFPyL PET/CT。总体阳性率79.2%(194/245),PSA和PSAdt是扫描阳性和骨盆外病变的独立预测因素,术后患者预测扫描阳性和骨盆外病变的AUC分别为78%和76%。

要点

  • 总体18F-DCFPyL PET/CT阳性率为79.2%(194/245)。
  • PSA<0.5 ng/mL组检出率48.2%(27/56),≥5.0 ng/mL组达91.8%(45/49)。
  • 术后患者中PSA和PSAdt是扫描阳性及骨盆外病变的独立预测因素。

核心结论

  • 18F-DCFPyL PET/CT在生化复发前列腺癌患者中提供高检出率。
  • PSA和PSAdt能够预测扫描阳性和疾病位置。
  • 骨或内脏病变的存在与较前列腺床仅复发病例更短的治疗后间隔相关。
  • 这些工具可能指导临床医生选择最适合进行18F-DCFPyL PET/CT显像的候选者。

研究设计与样本

  • 这是一项两机构研究,纳入245例原发性局部治疗后生化复发且常规影像阴性的前列腺癌患者。
  • 所有患者接受18F-DCFPyL PET/CT检查。
  • 采用多因素logistic回归分析确定扫描阳性的预测因素,并使用基于回归的系数开发预测扫描阳性和骨盆外病变的列线图。

主要发现

  • 总体79.2%(194/245)的患者18F-DCFPyL PET/CT结果为阳性。
  • PSA<0.5、0.5至<1.0、1.0至<2.0、2.0至<5.0和≥5.0 ng/mL组的检出率分别为48.2%(27/56)、74.3%(26/35)、84%(37/44)、96.7%(59/61)和91.8%(45/49)。
  • 病变局限于骨盆的患者PSA低于远处病变患者(1.6±3.5 vs. 3.0±6.3 ng/mL,P<0.001)。
  • 在接受前列腺切除术的患者(n=195)中,24.1%(47/195)扫描阴性,46.1%(90/195)显示骨盆内病变,29.7%(58/195)显示骨盆外病变。
  • 在放疗后亚组(n=50)中,PSA低于1.0 ng/mL时18F-DCFPyL PET/CT始终为阴性,仅当PSA大于2.0 ng/mL时可见骨盆外病变。

关键数值与推荐

  • 在术后患者中,PSA和PSAdt是扫描阳性和骨盆外病变存在的独立预测因素,曲线下面积分别为78%和76%。
  • 在放疗后队列中,PSA和PSAdt是骨盆外病变存在的独立预测因素,曲线下面积为85%。
  • 前列腺床仅复发病例从治疗到扫描的时间显著长于骨或内脏病变患者(6.2±6.4 vs. 2.4±1.3年,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to investigate the factors predicting scan positivity and disease location in patients with biochemical recurrence (BCR) of prostate cancer (PCa) after primary local therapy using prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT. Methods: This was a 2-institution study including 245 BCR PCa patients after primary local therapy and negative results on conventional imaging. The patients underwent 18F-DCFPyL PET/CT. We tested for correlations of lesion detection rate and disease location with tumor characteristics, time from initial therapy, prostate-specific antigen (PSA) level, and PSA doubling time (PSAdt). Multivariate logistic regression analyses were used to determine predictors of a positive scan. Regression-based coefficients were used to develop nomograms predicting scan positivity and extrapelvic disease. Results: Overall, 79.2% (194/245) of patients had a positive 18F-DCFPyL PET/CT result, with detection rates of 48.2% (27/56), 74.3% (26/35), 84% (37/44), 96.7% (59/61), and 91.8% (45/49) for PSAs of <0.5, 0.5 to <1.0, 1.0 to <2.0, 2.0 to <5.0, and ≥5.0 ng/mL, respectively. Patients with lesions confined to the pelvis had lower PSAs than those with distant sites (1.6 ± 3.5 vs. 3.0 ± 6.3 ng/mL, P < 0.001). In patients treated with prostatectomy (n = 195), 24.1% (47/195) had a negative scan result, 46.1% (90/195) showed intrapelvic disease, and 29.7% (58/195) showed extrapelvic disease. In the postradiation subgroup (n = 50), 18F-DCFPyL PET/CT was always negative at a PSA lower than 1.0 ng/mL and extrapelvic disease was seen only when PSA was greater than 2.0 ng/mL. At multivariate analysis, PSA and PSAdt were independent predictive factors of scan positivity and the presence of extrapelvic disease in postsurgical patients, with area under the curve of 78% and 76%, respectively. PSA and PSAdt were independent predictors of the presence of extrapelvic disease in the postradiation cohort, with area under the curve of 85%. Time from treatment to scan was significantly longer for prostatectomy-bed-only recurrences than for those with bone or visceral disease (6.2 ± 6.4 vs. 2.4 ± 1.3 y, P < 0.001). Conclusion:18F-DCFPyL PET/CT offers high detection rates in BCR PCa patients. PSA and PSAdt are able to predict scan positivity and disease location. Furthermore, the presence of bone or visceral lesions is associated with shorter intervals from treatment than are prostate-bed-only recurrences. These tools might guide clinicians to select the most suitable candidates for 18F-DCFPyL PET/CT imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mena E, Rowe SP, Shih JH, et al. Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. J Nucl Med. 2021. PMID: 34916246. doi:10.2967/jnumed.121.262347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。